OS Therapies Inc Terminates $18M At‑Market Sales Agreement

What Happened

• OS Therapies Inc (OSTX) filed a Form 8-K (Item 1.02) on July 29, 2026, announcing it delivered notice on July 23, 2026 to B. Riley Securities, Inc. and JonesTrading Institutional Services LLC to terminate its At Market Issuance Sales Agreement (dated August 8, 2025). The termination became effective July 28, 2026.
• Under the Sales Agreement and the related Prospectus Supplement (filed August 25, 2025), the company had authority to sell up to $18,000,000 of common stock; at termination it had sold 282,679 shares for aggregate gross proceeds of approximately $530,162, leaving about $17,469,838 unsold. No termination fees or other payments were due from either party.

Key Details

• Agreement parties: OS Therapies, B. Riley Securities, Inc., and JonesTrading Institutional Services LLC.
• Sales Agreement date: August 8, 2025; Prospectus Supplement filed: August 25, 2025.
• Shares sold under the facility: 282,679 shares for ~$530,162 gross proceeds.
• Remaining capacity at termination: ~$17,469,838; termination effective July 28, 2026; no fees paid.

Why It Matters

• The company no longer can offer or sell common stock under this specific at‑market sales facility, removing a previously available means to raise up to $18 million in equity financing.
• Investors should note the company’s disclosed historical use of the facility (small amount sold to date) and watch for future SEC filings announcing any replacement financing arrangements or alternative capital-raising actions.